New Alliance Equips Independent Psychiatry for Next-Gen Treatments

SAN FRANCISCO & BUFFALO, N.Y. – April 09, 2026 – A new exclusive partnership is set to reshape the landscape for independent psychiatry practices across the nation, granting them the purchasing power and operational muscle typically reserved for large hospital systems. Osmind, a technology platform supporting over 1,000 clinics, and CareNet GPO, a group purchasing organization (GPO) focused on behavioral health, have joined forces to tackle a critical barrier in mental healthcare: the accessibility and financial sustainability of innovative treatments.

For years, smaller, independent psychiatric practices have been at a disadvantage. While breakthrough therapies for conditions like treatment-resistant depression have emerged, their high cost and complex administrative requirements have often placed them out of reach for clinics without the backing of a major health network. This collaboration aims to directly dismantle that barrier, creating a more equitable playing field where the latest advancements in mental healthcare can be offered by the local clinicians on the front lines.

Leveling the Playing Field for Mental Healthcare

Independent psychiatry practices form the backbone of community mental health services in the United States. Yet, they often struggle to compete. Lacking the scale of large institutions, they cannot negotiate competitive pricing for specialty medications, making it difficult to offer cutting-edge treatments without facing significant financial strain. This new alliance directly confronts this disparity by pooling the collective buying power of its members.

CareNet GPO leverages this collective power to negotiate lower prices on specialty drugs and supplies, starting with SPRAVATO® (esketamine), a nasal spray for treatment-resistant depression. Membership in the GPO is offered at no cost to the practices themselves, allowing them to realize immediate savings. This financial relief is crucial for the sustainability of clinics that are vital to their communities.

“The moment a clinician decides a treatment is right for their patient, everything else should fall into place," said Jimmy Qian, Co-Founder and President at Osmind, in a statement announcing the partnership. "That's why this partnership with CareNet GPO matters. From drug pricing and compliance to peer support and shared resources, independent practices now have the same advantages as large health systems—without giving up any independence.”

This move is designed to empower clinicians to focus on patient care rather than procurement logistics and pricing battles, ensuring that clinical decisions are not constrained by a practice's balance sheet.

Taming the Complexity of Next-Generation Treatments

The challenge of offering advanced therapies extends far beyond just the sticker price. Many next-generation psychiatric treatments come with significant operational hurdles. SPRAVATO®, for instance, is subject to a mandatory FDA Risk Evaluation and Mitigation Strategy (REMS) program due to its potential side effects. This requires certified healthcare settings, specialized staff training, and rigorous patient monitoring and documentation—a heavy administrative lift for a small practice.

This is where the integration with Osmind's technology platform becomes a key differentiator. Practices using the software gain access to interventional-tailored clinical workflows and REMS compliance automation, which streamline the complex documentation and reporting required. The partnership also provides end-to-end “buy-and-bill” support, a notoriously complex reimbursement process for specialty drugs. This includes guidance on procurement, billing, and even distributor setup through Cencora (Besse Medical), effectively offloading a major administrative burden from clinic staff.

While SPRAVATO® is the initial focus, the partnership is built for a future where the pipeline of psychiatric innovation continues to deliver. The landscape already includes other advanced options like ketamine infusion therapy and transcranial magnetic stimulation (TMS), and the pharmaceutical pipeline is robust with novel agents for depression, schizophrenia, and other disorders. By establishing this infrastructure now, the network is preparing to rapidly integrate future therapies as they receive FDA approval, ensuring they reach patients faster.

More Than Savings: Building a Collaborative Network

Beyond the financial and operational benefits, the partnership fosters a sense of community in a field that can often be isolating. Members gain access to the Psychiatry Collective, a community of over 2,700 clinicians dedicated to interventional psychiatry. This peer network serves as an invaluable resource for ongoing education, sharing best practices, and collaborative problem-solving in a rapidly evolving specialty.

This collaborative element is critical as clinicians navigate the nuances of new treatments. The ability to consult with peers on complex cases, discuss implementation strategies, and stay abreast of the latest research can directly translate to improved patient outcomes. It transforms a network of disparate, independent practices into a connected ecosystem of shared knowledge.

“CareNet GPO was built by clinicians who believe interventional psychiatry should be accessible to everyone,” noted Katie Passanisi, Managing Director for CareNet GPO. “Independent practices shouldn't have to choose between offering the right treatment and keeping the lights on. This partnership makes sure they don't.”

A New Channel for Psychiatric Innovation

The implications of this consolidated network extend to the life sciences companies developing the next wave of psychiatric drugs. Historically, reaching a fragmented market of thousands of small, independent practices has been a significant marketing and logistical challenge for pharmaceutical manufacturers. This partnership changes that dynamic.

It offers life sciences companies a single, defined, and scalable channel to reach a highly engaged network of over 1,000 interventional psychiatry practices. This can dramatically accelerate the adoption of new therapies by pre-qualifying a network of clinics that are already equipped—both financially and operationally—to administer them. For an industry looking to bring novel treatments to market efficiently, this streamlined access is a powerful proposition.

Furthermore, Osmind's technology platform is positioned to gather crucial real-world evidence on patient outcomes. This data is invaluable for pharmaceutical companies for post-market surveillance and for demonstrating a treatment's effectiveness outside the controlled environment of a clinical trial. By creating a powerful trifecta of purchasing power, technological efficiency, and a connected clinical community, the Osmind-CareNet GPO alliance is not just supporting existing practices; it is building the infrastructure for the future of psychiatric care delivery.